Our best long-term strategy is to rely on the mRNA vaccines like Pfizer and Moderna.
Articles on Pfizer-BioNTech vaccine
Displaying 81 - 100 of 148 articles
It’s normal for different people to mount stronger or weaker immune responses to a vaccine, but post-shot side effects won’t tell you which you are.
The one-dose vaccine developed by Johnson & Johnson is temporarily halted because of potentially serious blood clots seen in six women. An immunologist explains what this means for you.
A vaccine expert breaks down everything you need to know about the Novavax vaccine.
This week’s unwelcome medical advice about the AstraZeneca vaccine is the latest setback to the rollout and the Morrison government.
Even with the highest possible rates of vaccination, New Zealand will need to keep up public health measures, or consider letting go of the concept of elimination and focus instead on disease control.
New CDC guidance permits domestic travel for fully vaccinated individuals, as long as social distancing is respected. International travel guidelines are different.
Good news for children and young people, bad news for Johnson & Johnson.
Many people never experience the least bit of discomfort from the COVID-19 vaccines, but mild side effects are common. They include swelling in the affected arm, nausea and chills.
An immunologist explains that you get some protection from the first dose of the mRNA vaccines but you need two to build up strong immunity, particularly to newer coronavirus variants.
It’s not too late for Australia to repair our vaccine strategy, though we will never make up for the months lost.
Injected vaccines tend to generate good immunity overall but less of a response in the nose and throat, where the virus enters and spreads from.
The risk of COVID escaping from hotel quarantine or a health-care setting will never be zero. But in NSW and Queensland, was everything possible done to minimise the risk?
With four COVID-19 vaccines approved for use in Canada, it’s time to answer FAQs about efficacy, immunity, eradication and variants.
Millions of vaccinated people have been waiting for guidelines on what they can do safely. The CDC says it’s OK to gather with other vaccinated people, but it’s still best to avoid travel.
Researchers are closely watching the coronavirus mutants to make sure vaccines can be adjusted if necessary. But scientists don’t know whether vaccines will be effective in those already vaccinated.
You’ve been vaccinated; can you now safely see your friends and family? New research hints that vaccinated people may be less likely to transmit the coronavirus, but they are not 100% in the clear.
The clock starts ticking once the vaccine leaves the freezer. Here’s what to expect.
Australia should pivot to a high-efficacy vaccine like Pfizer or Novavax to give us the best chance of achieving herd immunity.
Over 130 million doses have already been administered worldwide. It’s early days, but the signs are promising in places like Israel and the UK.
Top contributors
-
Professor of Medicine, University of Virginia
-
Associate Professor of Pediatrics, University of Virginia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor, The Children's Hospital at Westmead Clinical School and Sydney Infectious Diseases Institute, University of Sydney
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Pediatric Infectious Diseases Fellow, University of Pittsburgh
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Instructor of Human Immunology, Emory University
-
Chair in Epidemiology, Deakin University
-
Associate Professor in Viral Immunology, University of Birmingham
-
Deputy Director of the HUMLOG (Humanitarian Logistics and Supply Chain Management Research) Institute, Hanken School of Economics
-
Professor of Health Service Operations, School of Pharmacy & Medical Sciences, University of Bradford